Search

Your search keyword '"Goebeler M"' showing total 855 results

Search Constraints

Start Over You searched for: Author "Goebeler M" Remove constraint Author: "Goebeler M"
855 results on '"Goebeler M"'

Search Results

4. 118O Definitive results for NSCLC and bladder cancer cohorts in the phase IIa trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)

5. PB1334 Safety Profile of Efgartigimod from Clinical Trials in Participants with Immunoglobulin G-Mediated Autoimmune Diseases

8. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

16. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

17. EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors

18. 729MO Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment

20. Impact of off‐label use regulations on patient care in dermatology – a prospective study of cost‐coverage applications filed by tertiary dermatology clinics throughout Germany

21. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

23. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

26. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial

27. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway

28. Impaired FoxP3+ Treg function and epigenetic modulations at the FoxP3 enhancer, promotor and TSDR regions by Th17-inducing cytokines in patients with psoriatic arthritis

30. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

33. LB773 Treating pemphigus vulgaris (PV) and foliaceus (PF) by inhibiting the neonatal Fc receptor: Phase 2 multicentre open-label trial with efgartigimod

34. Erratum: Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

41. Phlebologie an deutschen Hautkliniken: Eine Bestandsaufnahme im Auftrag der Deutschen Gesellschaft für Phlebologie

47. Proportions of regulatory T cells (Treg) and suppressive Treg function in patients with psoriasis arthritis (PsA) or spondyloarthritis (SpA) after switching to anti-IL-17 treatment

Catalog

Books, media, physical & digital resources